Regeneron ( Regeneron)

Primary tabs

Regeneron's picture

Management

Contact Address

About Regeneron

At Regeneron we make it our business every day to bring innovative thinking to the challenge of discovering and developing new medicines. Our pursuit has one singular intent – to improve therapeutic outcomes for patients.

Regeneron press release, blog etc

Fri, 03/15/2019 - 14:56 Praluent (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
Wed, 03/13/2019 - 07:51 Regeneron and Sanofi to Present New Praluent (alirocumab) Data at ACC.19
Tue, 03/12/2019 - 00:57 Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Classic Math Problem
Mon, 03/11/2019 - 17:57 FDA Approves Dupixent (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
Mon, 03/11/2019 - 00:02 New Genetic Data from Regeneron and GSK on 50,000 UK Biobank Participants Made Available to Global Health Research Community
Fri, 03/08/2019 - 16:47 Regeneron Announces Upcoming Investor Conference Call
Fri, 03/08/2019 - 08:36 FDA to Undertake Priority Review of Dupixent (dupilumab) for Adults with Inadequately Controlled Severe Chronic Rhinosinusitis with Nasal Polyps
Fri, 03/01/2019 - 13:37 CHMP Recommends Approval of Dupixent (dupilumab) for Asthma Indication
Fri, 03/01/2019 - 12:55 New Analyses to Be Presented at AAD for Dupixent (dupilumab) and the Burden of Atopic Dermatitis
Sun, 02/24/2019 - 22:12 Regeneron and Sanofi Strongly Disagree with Verdict Upholding Three of Five Amgen U.S. Patent Claims Relating to PCSK9 Antibodies
Thu, 02/14/2019 - 22:41 U.S. and EU Patent Office Decisions Invalidate Amgen Subsidiary Immunex's Patents Claiming Antibodies to the IL-4 Receptor
Mon, 02/11/2019 - 14:32 Regeneron and Sanofi Offer Praluent (alirocumab) at a New Reduced U.S. List Price
Sat, 02/09/2019 - 15:16 One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium
Mon, 02/04/2019 - 15:17 CHMP Recommends Approval of Praluent (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease
Wed, 01/23/2019 - 13:22 Forty of the Nation's Most Brilliant Young Scientists Named Finalists in Regeneron Science Talent Search 2019
Mon, 01/07/2019 - 07:22 Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
Mon, 01/07/2019 - 05:46 Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference
Sat, 12/01/2018 - 05:02 Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma